DOR at 12 months among YA patients achieving remission who received tisa-cel compared with those who received brexu-cel. DOR was 41% for YA patients receiving tisa-cel (95% CI, 27-61) and 61% for those receiving brexu-cel (95% CI, 41-93); HR, 2.55; 95% CI, 1.01-6.42; P = .12. DOR was censored for allogeneic stem cell transplant in remission and last follow-up. Time 0 was defined as day 28 after CAR T infusion, which was the first time point of established remission.